Dupilumab: Phase III data

The double-blind, international Phase III LIBERTY AD CHRONOS trial in 740 patients with inadequately controlled moderate to severe atopic dermatitis showed that 300 mg subcutaneous dupilumab once

Read the full 279 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE